42754-96-1

Basic information

• Product Name: 4,6-DICHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE
• Synonyms: 4,6-DICHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE;1H-Pyrazolo[3,4-d]pyrimidine,4,6-dichloro-;4,6-dichloropyrrolo[2,3-d]pyrimidine;4,6-Dichloro-1H-pyrazole[3,4-D]pyriMidine;4,6-Dichloropyrazolo[3,4-d]pyriMidine;6-Dichloro-1H-pyrazolo[3;4,6-dichloro-1H-pyrazolo[3,4-d]pP03119ine;4,6-DICHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(RS20012005)
• CAS NO: 42754-96-1
• Molecular Formula: C₅H₂Cl₂N₄
• Molecular Weight: 189
• EINECS: 948-193-9
• Product Categories: CHIRAL CHEMICALS;Building Blocks;Pyrazolo[x,x-y]pyridine;Aromatics;Heterocycles;Heterocycle-Pyrimidine series
• Mol File: 42754-96-1.mol
• Article Data: 16

Chemical Properties

• Melting Point: 145 °C (decomp)
• Boiling Point: 251.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.792 g/cm³
• Refractive Index: 1.742
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 7.90±0.20(Predicted)
• CAS DataBase Reference: 4,6-DICHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-DICHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(42754-96-1)
• EPA Substance Registry System: 4,6-DICHLORO-1H-PYRAZOLO[3,4-D]PYRIMIDINE(42754-96-1)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45-24/25
• RIDADR: UN2811
• HazardClass: IRRITANT
• Hazardous Substances Data: 42754-96-1(Hazardous Substances Data)

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C5H2Cl2N4/c6-3-2-1-8-11-4(2)10-5(7)9-3/h1H,(H,8,9,10,11)

Upstream product

• 50270-27-4 2,4,6-trichloropyrimidine-5-carbaldehyde 
• 302-01-2 hydrazine 
• 2465-59-0 oxypurinol 
• 184764-63-4 4,6-dihydroxypyrazolo[3,4-d]pyrimidine 

Downstream Products

• 1144080-48-7 6-chloro-4-(8-oxa-3-aza-bicyclo[3.2.1]oct-3-yl)-1H-pyrazolo[3,4-d]pyrimidine 
• 7152-45-6 6-dimethylamino-1,5-dihydro-pyrazolo[3,4-d]pyrimidine-4-thione 
• 2537-04-4 6-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 
• 6288-89-7 4,6-Bis-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidine 
• 7251-92-5 6-chloro-N-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 528577-55-1 1-(2-{[tert-butyl(diphenyl)silyl]oxy}butyl)-6-[(3,4-dichlorobenzyl)amino]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 528577-54-0 1-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)-6-[(3,4-dichlorobenzyl)amino]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 528577-53-9 1-(2-{[tert-butyl(diphenyl)silyl]oxy}butyl)-6-chloro-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 528577-52-8 1-(2-{[tert-butyl(diphenyl)silyl]oxy}ethyl)-6-chloro-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 637768-58-2 6-chloro-2-(2-deoxy-5-O-(4,4'-dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl)-4-{[(di-n-butylamino)methylidene]amino}-2H-pyrazolo[3,4-d]pyrimidine 
• 637768-59-3 6-chloro-1-(2-deoxy-5-O-(4,4'-dimethoxytriphenylmethyl)-β-D-erythro-pentofuranosyl)-4-{[(di-methylamino)methylidene]amino}-1H-pyrazolo[3,4-d]pyrimidine 
• 637768-53-7 6-chloro-1-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-isopropoxy-1H-pyrazolo[3,4-d]pyrimidine 
• 637768-54-8 6-chloro-2-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-isopropoxy-2H-pyrazolo[3,4-d]pyrimidine 
• 1017246-07-9 C₁₁H₈ClN₅ 

Relevant articles and documents

SHP2 INHIBITORS AND USES THEREOF

Compounds of Formula 1 as inhibitors of protein tyrosine phosphatase SHP2 are disclosed. The pharmaceutical compositions comprising compounds of Formula 1, methods of synthesis of these compounds, methods of treatment for diseases associated with the aberrant activity of SHP2 such as cancer using these compounds or compositions containing these compounds are also disclosed.

Novel pyrazolo[3,4-d]pyrimidine with 4-(1H-benzimidazol-2-yl)-phenylamine as broad spectrum anticancer agents: Synthesis, cell based assay, topoisomerase inhibition, DNA intercalation and bovine serum albumin studies

A series of new pyrazolo[3,4-d]pyrimidine possessing 4-(1H-benzimidazol-2-yl)-phenylamine moiety at C4 position and primary as well as secondary amines at C6 position has been designed and synthesized. Their antitumor activities were evaluated against a panel of 60 human cancer cell lines at National Cancer Institute (NCI). Six compounds displayed potent and broad spectrum anticancer activities at 10?μM. Compounds 8, 12, 14 and 17 proved to be the most active and efficacious candidate in this series, with mean GI50values of 1.30?μM, 1.43?μM, 2.38?μM and 2.18?μM, respectively against several cancer cell lines. Further biological evaluation of these compounds suggested that these compounds induce apoptosis and inhibit human topoisomerase (Topo) IIα as a possible intracellular target. UV-visible and fluorescence studies of these compounds revealed strong interaction with ct-DNA and bovine serum albumin (BSA).

LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME

Compounds having the formula (I), (II), (III) are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.